癌症相关静脉血栓栓塞症低分子肝素治疗延续情况:一项日常临床实践中的前瞻性队列研究
该前瞻性队列研究纳入荷兰和西班牙四家医院的活动性癌症合并客观确诊症状性近端深静脉血栓和/或肺栓塞的连续患者,评估低分子肝素(LMWH)治疗期间的延续率与并发症。中位90天后LMWH停药的累积发生率为21%,仅女性与提前停药显著相关(OR 1.6,95%CI 1.03-2.5)。
要点
- 中位90天时LMWH停药的累积发生率为21%(95%CI 17-25)。
- 仅女性与提前停用LMWH显著相关(OR 1.6,95%CI 1.03-2.5)。
- 8.1%复发VTE、8.3%大出血、28%死亡。
核心结论
- 五分之一癌症相关VTE患者因副作用停止LMWH注射。
- 该发现为当前比较直接口服抗凝药与LMWH疗效和安全性的临床试验提供了相关背景信息。
研究设计与样本
- 前瞻性队列研究,在荷兰三家医院和西班牙一家医院纳入活动性癌症合并客观确诊症状性近端深静脉血栓和/或肺栓塞的连续患者,评估LMWH治疗期间的延续情况。
- 排除接受其他抗凝药、失访或发生静脉导管相关血栓的患者。
- 共分析372例患者,LMWH治疗最长180天。
主要发现
- 中位90天(四分位距60-120天)后LMWH停药的累积发生率为21%(95%CI 17-25)。
- 仅女性与提前停用LMWH显著相关(OR 1.6,95%CI 1.03-2.5)。
- 30例患者(8.1%)发生复发VTE。
- 30例患者(8.3%)发生大出血。
- 106例患者(28%)死亡。
关键数值与推荐
- 当前指南推荐LMWH单药治疗3-6个月作为癌症相关VTE的一线治疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Essentials Low-molecular-weight heparin (LMWH) injections for venous thromboembolism (VTE) may be burdensome. Patients with active cancer and confirmed VTE were included to evaluate LMWH continuation. The cumulative incidence of discontinuation was 21% after a median period of 90 days. One out of five patients discontinued LMWH injections because of side effects. SUMMARY: Background Current guidelines recommend low-molecular-weight heparin (LMWH) monotherapy for 3-6 months as the first-line treatment for cancer-associated venous thromboembolism (VTE). However, although daily administration of LMWH injections over a course of several months may be burdensome, the number of patients who stop treatment because of LMWH side-effects is unknown. Objectives To evaluate the continuation rate and complications of daily LMWH injections in patients with cancer-associated VTE. Methods Consecutive patients with active cancer and objectively confirmed symptomatic proximal deep vein thrombosis and/or pulmonary embolism, treated at three Dutch hospitals and one Spanish hospital, were included to evaluate continuation LMWH therapy during LMWH treatment. Patients were excluded when they received other anticoagulants, were lost to follow-up, or experienced a venous catheter-associated thrombosis. Results A total of 372 patients were analyzed during LMWH treatment for a maximum of 180 days. The cumulative incidence of discontinuation was 21% (95% confidence interval [CI] 17-25) after a median period of 90 days (interquartile range 60-120 days). Only female sex was found to be significantly associated with premature LMWH discontinuation (odds ratio 1.6; 95% CI 1.03-2.5). Thirty patients (8.1%) developed recurrent VTE, 30 patients (8.3%) suffered a major bleed, and 106 patients (28%) died. Conclusion Our study reveals that one of five patients with cancer-associated VTE stopped LMWH injections because of side-effects. This finding provides relevant background information for current clinical trials investigating the efficacy and safety of direct oral anticoagulants as compared with LMWH.
引用
- van der Wall SJ, Klok FA, den Exter PL, et al. Continuation of low-molecular-weight heparin treatment for cancer-related venous thromboembolism: a prospective cohort study in daily clinical practice. J Thromb Haemost. 2016. PMID: 28012224. doi:10.1111/jth.13563
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。